assessing i-sabr in early or recurrent non-small cell lung cancer
Published 10 months ago • 110 plays • Length 0:51Download video MP4
Download video MP3
Similar videos
-
1:49
a phase ii study of i-sabr in early or recurrent nsclc
-
1:08
the future of i-sabr in lung cancer
-
1:51
outcomes of i-sabr in lung cancer
-
1:12
updates in early stage non-small cell lung cancer
-
1:53
assessing targeted therapies in early stage nsclc
-
0:28
stereotactic ablative radiotherapy (sabr) for lung cancer treatment
-
1:22
real-world dfs as a predictor of os in resected early-stage non-small cell lung cancer
-
2:20
sabr improves outcomes for stage 1 lung cancer
-
1:31
asco 2023: highlights in non-small cell lung cancer
-
2:43
targeted therapy for early-stage lung cancer
-
1:01
targeting alk rearrangements in non-small cell lung cancer
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
1:13
early detection and interception in lung cancer
-
2:05
assess trial: blood test for egfr mutation in advanced non-small cell lung cancer
-
1:52
is adjuvant immunotherapy necessary in non-small cell lung cancer?
-
2:18
stereotactic radiotherapy vs surgery in early-stage ncslc
-
0:41
unmet needs in kras-driven non-small cell lung cancer
-
1:02
evaluating the role of systemic therapies in sclc